When was Gilgamesh founded?

Gilgamesh was founded in 2019 and raised its 1st funding round 1 year after it was founded.

Where is Gilgamesh located?

Gilgamesh is headquartered in New York City, United States. It is registered at 113 University Place, Suite 1019, NY, NY 10003.

Who is the current CEO of Gilgamesh?

Jonathon Sporn of Gilgamesh. They have also founded 1 company.

Is Gilgamesh a funded company?

Gilgamesh is a funded company, having raised a total of $152M across 16 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Apr 01, 2020.

How much is Gilgamesh worth?

The latest valuation of Gilgamesh is $***** as of Mar 24, 2026.

When was the latest funding round of Gilgamesh?

Gilgamesh's latest funding was a $***** Series B round on Mar 27, 2026, with participation from 0 investor. Its primary sector is Neurology. In United States, the Neurology sector has seen $4.75B in funding in 2026 to date.

Where does Gilgamesh rank among its competitors?

Gilgamesh ranks 3rd amongst 36 active competitors, of which 10 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Psilera, which secured $8.8M in May, 2026.

Who are the top competitors of Gilgamesh?

Gilgamesh's top competitors include COMPASS Pathways, MindMed and Cybin. Among them, Psilera secured the most recent funding round in May, 2026.

Gilgamesh - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of drugs for neuropsychiatric conditions. The company has an AI-powered discovery and translational platform to develop novel psychotropic drugs for the treatment of neuropsychiatric conditions including depression, anxiety, substance use, and stress-related disorders. Products include GM-1020 and GM-2505 an oral NMDAR Antagonist.

Website: www.gilgameshpharmaceutical.com/
Social
Email ID: *****@gilgameshpharmaceutical.com
Registered Address: 113 University Place, Suite 1019, NY, NY 10003

Key Metrics

Founded Year

2019

Location

New York City, United States

Stage

Series B

Total Funding

$152M in 16 rounds

Latest Funding Round

Series B, Mar 27, 2026, $*****

Post Money Valuation

$***** as on Mar 24, 2026

Investors

Prime Movers Lab & 19 more

Ranked

3^rd among 36 active competitors

Similar Companies

COMPASS Pathways & 42 more

View Gilgamesh's full profile

Gilgamesh is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
GILGAMESH PHARMACEUTICALS, INC. CIN: 84-2552195 , United States, Active	Jul 18, 2019	-	2 (As on Dec 31, 2020)	-

Gilgamesh has raised a total funding of $152M over 16 rounds. Its first funding round was on Apr 01, 2020. Gilgamesh has 19 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Gilgamesh:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 27, 2026	2174385	Series B	8620896	4646012	3170226	1501049
Mar 09, 2026	6391382	Series B	6273786	8388710	2334917	Prime Movers Lab
Jan 02, 2026	7132843	Series B	1759449	3965661	5783774	6575324

Access funding benchmarks and valuations. Sign up today!

View details of Gilgamesh's funding rounds and investors

The founders of Gilgamesh are Mike Cunningham, Dalibor Sames, Jonathon Sporn, Andrew Kruegel and Jeff Witkin. Jonathon Sporn is the CEO of Gilgamesh.

Here are the details of Gilgamesh's key team members:

Mike Cunningham: Co-Founder of Gilgamesh. They serve on the board of 1 company.
Dalibor Sames: Co-Founder & CSO of Gilgamesh.
Jonathon Sporn: Co-Founder & CEO of Gilgamesh.
Andrew Kruegel: Co-Founder of Gilgamesh.
Jeff Witkin: Co-Founder of Gilgamesh.

View details of Gilgamesh's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Gilgamesh include COMPASS Pathways, MindMed and Cybin. Here is the list of Top 10 competitors of Gilgamesh, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	COMPASS Pathways 2016, London (United Kingdom), Public	Developer of therapies for treating mental disorders	$109M	Perceptive Advisors, Able Partners & 20 others	66/100
2nd	MindMed 2019, New York City (United States), Public	Developer of psychedelic-based therapies for brain health disorders	-	TR Ventures, K2 HealthVentures & 9 others	58/100
3rd	Gilgamesh 2019, New York City (United States), Series B	Developer of drugs for neuropsychiatric conditions	$152M	Seven Hound Ventures, Satori Capital & 18 others	57/100
4th	Cybin 2002, Toronto (Canada), Public	Provider of psychedelic therapeutics for psychiatric disorders	-	Hightrailcapital, Subversive Capital & 10 others	56/100
5th	Delix Therapeutics 2019, Menlo Park (United States), Series A	Developer of therapeutic solutions for the treatment of multiple neurological disorders	$100M	RA Capital Management, Artis Ventures & 22 others	55/100
6th	Psilera 2019, Tampa (United States), Seed	Manufacturer of natural-based medicines for the treatment of mental health illnesses	$11.3M	Iter Investments, What If Ventures & 4 others	48/100
7th	Tryp Therapeutics 2020, Kelowna (Canada), Public	Developer of therapeutic solutions for treating neuropsychiatric disorders & pain	-	-	48/100
8th	Neural Therapeutics 2020, Toronto (Canada), Public	Developer of ethnobotanical drug for neurological disorder	$495K	-	47/100
9th	Psyence 1997, Toronto (Canada), Public	Developer of psychedelic therapeutics for mental health disorders	-	-	47/100
10th	Eleusis 2013, London (United Kingdom), Acquired	Developer of immunomodulatory and neuroprotective medicines	$1.47M	Palo Santo, Noetic Psychedelic Fund & 4 others	47/100